PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 417/12, A61K 31/425 | A1

(11) International Publication Number: WO 99/31094

(43) International Publication Date: 24 June 1999 (24.06.99)

(21) International Application Number: PCT/EP98/08154

(22) International Filing Date: 14 December 1998 (14.12.98)

(30) Priority Data:
9726568.0 16 December 1997 (16.12.97) GB

(71) Applicant *(for all designated States except US)*: SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: BLACKLER, Paul, David, James [GB/GB]; SmithKline Beecham Pharmaceuticals, Old Powder Mills, Near Leigh, Tonbridge, Kent TN11 9AN (GB). LEE, David, C. [GB/GB]; SmithKline Beecham Pharmaceuticals, The Frythe, Welwyn, Hertfordshire AL6 9AR (GB). SASSE, Michael, John [GB/GB]; SmithKline Beecham Pharmaceuticals, Old Powder Mills, Near Leigh, Tonbridge, Kent TN11 9AN (GB).

(74) Agent: RUTTER, Keith; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: HYDRATE OF 5–[4–[2– (N–METHYL–N– (2–PYRIDIL)AMINO) ETHOXY]BENZYL] THIAZOLIDINE–2, 4–DIONE MALEIC ACID SALT

(57) Abstract

A hydrate of 5–[4–[2– (N–methyl–N– (2–pyridyl)amino) ethoxy]benzyl] thiazolidine–2, 4–dione, maleic acid salt, characterised in that it: (i) comprises water in the range of from 0.2 to 1.1 % w/w; and (ii) provides an infrared spectrum containing peaks at 764 and 579 cm^{-1}; and/or (iii) provides an X–ray powder diffraction (XRPD) pattern substantially as set out in Figure II; a process for the preparation of such a compound, a pharmaceutical composition containing such a compound and the use of such a compound or composition in medicine.